[Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. Inversion of the clinical development].

Abstract

A 21-year old male patient with Philadelphia chromosome-positive chronic myeloid leukaemia received an autologous bone marrow transplant in consolidation of the 2nd chronic phase. The bone marrow had been treated with mafosfamide in adequate doses. The post-transplantation course of the disease was marked by an inversion: the duration of the 2nd chronic phase was more than 4 times longer than that of the first one, suggesting some degree of effectiveness of autologous bone marrow transplantation performed in the 2nd chronic phase and/for of the in vitro treatment of the bone marrow with mafosfamide. Cytogenetic monitoring was pursued throughout the course of leukaemia: regression of the Philadelphia chromosome was only partial and transient, and 3 clones appeared, each of them involving chromosome 1, for which mafosfamide was most probably responsible.

• Authors: L Fouillard, J Van Den Akker, J P Laporte, A Najman, C Perot, M Lopez, L Douay, F Isnard, J L Taillemite, N C Gorin
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 18 Issue 36 Pg. 1785-8 (Nov 04 1989) ISSN: 0755-4982 [Print] France
• Vernacular Title: Autogreffe de moelle osseuse traitée par mafosfamide en phase d'accélération de leucémie myéloïde chronique. Inversion de l'évolution clinique.
• PMID: 2530566 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• mafosfamide
• Cyclophosphamide

Topics

• Adult
• Antineoplastic Agents (pharmacology)
• Bone Marrow (drug effects)
• Bone Marrow Transplantation
• Chronic Disease
• Cyclophosphamide (analogs & derivatives, pharmacology)
• Humans
• In Vitro Techniques
• Karyotyping
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics, surgery)
• Male
• Transplantation, Autologous